| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… |
Trial sites expanded: 7 -> 10 locations |
| 2026-08-05 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… |
Recruitment opened |
| 2026-08-05 | NCT07587242 A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… |
Trial sites expanded: 0 -> 7 locations |
| 2026-07-31 | NCT06244082 Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With… |
date change Completion moved earlier: 2027-07-31 -> 2027-04-30 |
| 2026-07-28 | NCT07038200 A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD |
Primary endpoint(s) modified |
| 2026-07-24 | NCT07008469 Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 |
Trial sites expanded: 26 -> 35 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07038200 | A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | Facioscapulohumeral Muscular Dystrophy | Recruiting |
| NCT07587242 | A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as… | Muscular Dystrophies | Recruiting |
| NCT06411288 | Global Study of Del-desiran for the Treatment of DM1 | DM1 | Active, Not Recruiting |
| NCT07008469 | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | Myotonic Dystrophy Type 1 | Enrolling by Invitation |
| Phase 2 | |||
| NCT06547216 | Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral… | FSHD | Active, Not Recruiting |
| NCT06244082 | Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With… | DMD | Active, Not Recruiting |